[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Hochhaus
A
A
III. Medizinische Universitätsklinik, Klinikum Mannheim, Universität Heidelberg, Wiesbadener Strasse 7-11, 68305 Mannheim. hochhaus@uni-hd.de
Berger
U
U
Reiter
A
A
Engelich
G
G
Lahaye
T
T
Kreil
S
S
Merx
K
K
Müller
M C
MC
Hehlmann
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002869:Chromosome Aberrations; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D010879:Piperazines / Q000008:administration & dosage; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea